381 related articles for article (PubMed ID: 28780679)
1. Locoregional therapies for hepatocellular carcinoma and the new LI-RADS treatment response algorithm.
Kielar A; Fowler KJ; Lewis S; Yaghmai V; Miller FH; Yarmohammadi H; Kim C; Chernyak V; Yokoo T; Meyer J; Newton I; Do RK
Abdom Radiol (NY); 2018 Jan; 43(1):218-230. PubMed ID: 28780679
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of treatment response in hepatocellular carcinoma in the explanted liver with Liver Imaging Reporting and Data System version 2017.
Seo N; Kim MS; Park MS; Choi JY; Do RKG; Han K; Kim MJ
Eur Radiol; 2020 Jan; 30(1):261-271. PubMed ID: 31418085
[TBL] [Abstract][Full Text] [Related]
3. Incorporation of Ancillary MRI Features Into the LI-RADS Treatment Response Algorithm: Impact on Diagnostic Performance After Locoregional Treatment of Hepatocellular Carcinoma.
Kim YY; Kim MJ; Yoon JK; Shin J; Roh YH
AJR Am J Roentgenol; 2022 Mar; 218(3):484-493. PubMed ID: 34585608
[No Abstract] [Full Text] [Related]
4. Evaluation of LI-RADS Version 2018 Treatment Response Algorithm for Hepatocellular Carcinoma in Liver Transplant Candidates: Intraindividual Comparison between CT and Hepatobiliary Agent-enhanced MRI.
Bae JS; Lee JM; Yoon JH; Kang HJ; Jeon SK; Joo I; Lee KB; Kim H
Radiology; 2021 May; 299(2):336-345. PubMed ID: 33650901
[TBL] [Abstract][Full Text] [Related]
5. LI-RADS treatment response categorization on gadoxetic acid-enhanced MRI: diagnostic performance compared to mRECIST and added value of ancillary features.
Kim SW; Joo I; Kim HC; Ahn SJ; Kang HJ; Jeon SK; Lee JM
Eur Radiol; 2020 May; 30(5):2861-2870. PubMed ID: 32006170
[TBL] [Abstract][Full Text] [Related]
6. LI-RADS M (LR-M): definite or probable malignancy, not specific for hepatocellular carcinoma.
Fowler KJ; Potretzke TA; Hope TA; Costa EA; Wilson SR
Abdom Radiol (NY); 2018 Jan; 43(1):149-157. PubMed ID: 28580538
[TBL] [Abstract][Full Text] [Related]
7. LI-RADS Treatment Response Algorithm: Performance and Diagnostic Accuracy.
Shropshire EL; Chaudhry M; Miller CM; Allen BC; Bozdogan E; Cardona DM; King LY; Janas GL; Do RK; Kim CY; Ronald J; Bashir MR
Radiology; 2019 Jul; 292(1):226-234. PubMed ID: 31038409
[TBL] [Abstract][Full Text] [Related]
8. LI-RADS: Past, Present, and Future, From the
Marks RM; Masch WR; Chernyak V
AJR Am J Roentgenol; 2021 Feb; 216(2):295-304. PubMed ID: 33052720
[TBL] [Abstract][Full Text] [Related]
9. Reproducibility of LI-RADS treatment response algorithm for hepatocellular carcinoma after locoregional therapy.
Abdel Razek AAK; El-Serougy LG; Saleh GA; Shabana W; Abd El-Wahab R
Diagn Interv Imaging; 2020 Sep; 101(9):547-553. PubMed ID: 32253141
[TBL] [Abstract][Full Text] [Related]
10. Per-patient Negative Predictive Value of the CT and MRI Liver Imaging Reporting and Data System Version 2018 Treatment Response Algorithm for Hepatocellular Carcinoma.
Hassan OT; Behr SC; Ohliger MA; Fowler KJ; Gill RM; Fidelman N; Mehta N; Choi HH
Radiology; 2023 Dec; 309(3):e222776. PubMed ID: 38112541
[TBL] [Abstract][Full Text] [Related]
11. LI-RADS major features: CT, MRI with extracellular agents, and MRI with hepatobiliary agents.
Santillan C; Fowler K; Kono Y; Chernyak V
Abdom Radiol (NY); 2018 Jan; 43(1):75-81. PubMed ID: 28828680
[TBL] [Abstract][Full Text] [Related]
12. LI-RADS-CEUS - Proposal for a Contrast-Enhanced Ultrasound Algorithm for the Diagnosis of Hepatocellular Carcinoma in High-Risk Populations.
Schellhaas B; Wildner D; Pfeifer L; Goertz RS; Hagel A; Neurath MF; Strobel D
Ultraschall Med; 2016 Dec; 37(6):627-634. PubMed ID: 27486793
[No Abstract] [Full Text] [Related]
13. Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter restropective study of 1,006 nodules.
Terzi E; Iavarone M; Pompili M; Veronese L; Cabibbo G; Fraquelli M; Riccardi L; De Bonis L; Sangiovanni A; Leoni S; Zocco MA; Rossi S; Alessi N; Wilson SR; Piscaglia F;
J Hepatol; 2018 Mar; 68(3):485-492. PubMed ID: 29133247
[TBL] [Abstract][Full Text] [Related]
14. Post-treatment CT LI-RADS categories: predictors of overall survival in hepatocellular carcinoma post bland transarterial embolization.
Ormiston WEL; Yarmohammadi H; Lobaugh S; Schilsky J; Katz SS; LaGratta M; Velayati S; Zheng J; Capanu M; Do RKG
Abdom Radiol (NY); 2021 Aug; 46(8):3738-3747. PubMed ID: 32968863
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic accuracy of contrast-enhanced ultrasound for the differential diagnosis of hepatocellular carcinoma: ESCULAP versus CEUS-LI-RADS.
Schellhaas B; Görtz RS; Pfeifer L; Kielisch C; Neurath MF; Strobel D
Eur J Gastroenterol Hepatol; 2017 Sep; 29(9):1036-1044. PubMed ID: 28562394
[TBL] [Abstract][Full Text] [Related]
16. Imaging After Locoregional Therapy for Hepatocellular Carcinoma with Emphasis on LIRADS Treatment Response Assessment Criteria.
Bajaj G; Sundaram K; Jambhekar K; Ram R
Semin Ultrasound CT MR; 2021 Aug; 42(4):318-331. PubMed ID: 34130846
[TBL] [Abstract][Full Text] [Related]
17. LI-RADS
Chernyak V; Santillan CS; Papadatos D; Sirlin CB
Abdom Radiol (NY); 2018 Jan; 43(1):111-126. PubMed ID: 28695233
[TBL] [Abstract][Full Text] [Related]
18. Assessment of hepatocellular carcinoma treatment response with LI-RADS: a pictorial review.
Voizard N; Cerny M; Assad A; Billiard JS; Olivié D; Perreault P; Kielar A; Do RKG; Yokoo T; Sirlin CB; Tang A
Insights Imaging; 2019 Dec; 10(1):121. PubMed ID: 31853668
[TBL] [Abstract][Full Text] [Related]
19. LI-RADS categories: concepts, definitions, and criteria.
Santillan C; Chernyak V; Sirlin C
Abdom Radiol (NY); 2018 Jan; 43(1):101-110. PubMed ID: 29038857
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic Performance of LI-RADS Treatment Response Algorithm for Hepatocellular Carcinoma: Adding Ancillary Features to MRI Compared with Enhancement Patterns at CT and MRI.
Park S; Joo I; Lee DH; Bae JS; Yoo J; Kim SW; Lee JM
Radiology; 2020 Sep; 296(3):554-561. PubMed ID: 32692297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]